The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. Re-imagining Radiology.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. Advantages of Alpha Emitter Therapy Over the past two decades, the radiological and chemical properties of alpha emitting isotopes have regained prominence in medical physics. Guarnaschelli in the webinar. References The Green Journal.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40